Great Point Partners’s Audentes Therapeutics BOLD Stock Holding History
Bought
Maintained
Sold
Other funds holding BOLD
Great Point Partners's BOLD Position: Q4 2019 in Review
Great Point Partners sold out of Audentes Therapeutics (BOLD) in Q4 2019, closing a stake of 2,485,000 shares — an estimated $69.8M sold.
Great Point Partners first reported a position in BOLD in Q4 2018 and held it in 4 quarters. The position peaked at $72.8M in Q2 2019. 187 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.
- Great Point Partners reported no remaining Audentes Therapeutics position as of Q4 2019 after selling out during the quarter.
- Great Point Partners sold 2,485,000 Audentes Therapeutics shares in Q4 2019, an estimated $69.8M.
- Great Point Partners first reported a position in Audentes Therapeutics in Q4 2018 and held it in 4 quarters.
- Great Point Partners's Audentes Therapeutics position peaked at $72.8M in Q2 2019.
- 187 funds tracked by Wall St. Rank held Audentes Therapeutics as of Q4 2019.
Based on Great Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.